FIELD: medicine, pharmacy.
SUBSTANCE: invention relates to a pharmaceutical composition possessing capacity to release the therapeutically effective dose of active substance rivastigmin and showing the time-controlled pattern. The pharmaceutical composition is designated for treatment of patients suffering with Alzheimer's diseases dementia from small to middle severity degree. Compositions show safety and time-controlled release pattern of active substance rivastigmin.
EFFECT: valuable medicinal and pharmaceutical properties of composition.
5 cl, 2 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NEW PROLONGED COMPOSITIONS FOR PERORAL ADMINISTRATION | 1999 |
|
RU2286766C2 |
| PHARMACEUTICAL COMPOSITIONS OF METABOTROPIC GLUTAMATE RECEPTOR 5 (MGLU5) ANTAGONISTS | 2011 |
|
RU2602955C2 |
| THE PHARMACEUTICAL COMPOSITIONS CONTAINING pH - DEPENDENT MEDICAL PRODUCT, THE pH MODIFIER AND THE SLOWING DOWN AGENT | 2006 |
|
RU2442574C2 |
| PHARMACEUTICAL COMPOSITIONS CONTAINING S1P RECEPTOR MODULATOR | 2007 |
|
RU2487703C2 |
| RASAGILINE COMPOSITIONS OF PROLONGED RELEASE AND USE THEREOF | 2011 |
|
RU2607595C2 |
| COMPOSITIONS OF ORALLY DISPERSIBLE TABLETS CONTAINING COMBINATIONS OF HIGH- AND LOW-DOSE THERAPEUTIC AGENTS | 2010 |
|
RU2554740C2 |
| PER ORALLY DECOMPOSING TABLET COMPOSITIONS, CONTAINING COMBINATIONS OF NON-OPIATE ANALGESICS | 2010 |
|
RU2567032C2 |
| TERBINAFINE SOLID MEDICINAL FORMULATION FOR ORAL ADMINISTRATION | 2002 |
|
RU2298402C2 |
| GALENICAL PREPARATIONS OF ORGANIC COMPOUNDS | 2010 |
|
RU2535090C2 |
| MEDICINAL CONTROLLED-RELEASING FORMS OF AZITHROMYCIN | 1995 |
|
RU2130311C1 |
